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ABSTRACT
OBJECT:  The  object  of  this  work  was  to  compare  the  frequency  of  three  polymorphic 
changes  in  the  RET proto-oncogene:  L769L  and  S836S  and  S904S  in  patients  with 
medullary thyroid carcinoma (MTC) (n=246) and in the general population (n=420 for SNP 
L769L and S904S; n=411 for SNP 836). We tried to investigate how the harboured SNPs 
affect  the age at  onset  of  sMTC and MTC in carriers of  known pathogenic  mutations at 
codons 634 and 791 of the  RET gene. RESULTS: A statistically significant difference was 
found in the frequency of the heterozygous change L769L in patients with sMTC (48.3%) and 
in unaffected individuals (39.5%). CONCLUSIONS: The presence of the polymorphic change 
L769L  in  the  RET gene  predisposes  to  the  development  of  sporadic  medullary  thyroid 
carcinoma  and  also  lowers  the  age  of  onset  of  MTC  in  carriers  of  the  homozygous 
polymorphic  variant  L769L.  The  presence  of  this  polymorphic  change  in  MTC  patients 
carrying at the same time the RET codon 634 mutation lowers the age of onset of MTC in 
this group.
INTRODUCTION
Medullary thyroid carcinoma (MTC) is a malignant tumor originating from parafollicular 
C cells that produce calcitonin and accounts for 5-10% of all thyroid cancers. MTC develops 
in either sporadic (75%) or hereditary form (25%). In the inherited form, MTC appears in 
three cancer syndromes: FMTC (familial medullary thyroid carcinoma), MEN2A and MEN2B 
(multiple endocrine neoplasia type 2).
The hereditary form of MTC is associated with the development of germline changes 
in the RET gene. The RET (REarranged during Transfection) gene localized to 10q11.2 was 
identified in 1985 (1). The RET gene encodes a receptor tyrosine kinase and is expressed in 
the neural crest cells and neural crest-derived tissues (2, 3). The germline mutations of the 
RET gene causing increased receptor activation (gain-of-function mutations) are responsible 
for the FMTC, MEN2A (e.g. exon 10, codons 609, 611, 620) and MEN2B (e.g. exon 16, 
codon 918) cancer syndromes, while germline mutations of the RET gene leading to loss of 
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receptor  tyrosine  kinase  activity  (loss-of-function  mutations)  are  responsible  for  the 
development of Hirschsprung’s disease (4, 5).
In our earlier article we presented a spectrum of the RET gene mutations prevalent in 
the population of  Central  Poland (6).  It  represents the majority of mutations of  this gene 
reported in the world literature (7, 8, 9). The highest number of mutations were identified at  
codons 634 (26.8%) and 791 (20.9%).
In the RET gene, apart from clearly pathogenic mutations, also polymorphic changes in the 
DNA sequence were found. These are frequent changes (frequency above 1%) of several 
nucleotides  in  the  DNA  of  the  human  population.  They  are  divided  into:  mini  and 
microsatellite  sequences  polymorphisms  and  single  nucleotide  polymorphisms  (SNPs). 
SNPs make up about 90% of all the human genome variations and occur every 100 to 300 
bases along the 3-billion-base human genome (10).
A SNP in which the amino acid sequence of protein that is produced is altered due to 
single nucleotide polymorphism is termed non-synonymous. Synonymous SNPs do not lead 
to a change in the amino acid sequence. Studies conducted over the past few years revealed 
the effect of synonymous mutations on predisposition to develop cancer. To date, several 
types  of  SNPs  have  been  identified  in  the  RET gene:  G691S/exon  11,  GTT/AGT; 
L769L/exon 13, CTT/CTG; S836S/exon 14, AGC/AGT; S904S/exon 15, TCC/TCG. These 
changes were present both in affected individuals (endocrine tumors, MTC, PTC, HSCR) as 
well as in the non-affected population (11, 12). Among the several known SNPs, only one 
change, in exon 11 G691S, results in the substitution of another amino acid in the protein 
chain (13). 
In our group of patients three types of single-nucleotide polymorphisms were found in 
the RET gene in exons 13 (L769L), 14 (S836S) and 15 (S904S). These molecular variants 
appeared in one or both alleles of affected and non-affected individuals.
The aim of our study was to compare the frequency of occurrence of three SNPs: 
L769L, S836S and S904S, in patients with sporadic medullary thyroid carcinoma and in non-
affected individuals. Furthermore, we studied the effect of carrying homo- and heterozygous 
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polymorphic variant L769L on the age at onset of the sporadic and familial medullary thyroid 
carcinoma.
MATERIALS AND METHODS
Patients
246 patients, from Central Poland, with histological changes consistent with medullary 
thyroid cancer (MTC), treated at the Warsaw Oncology Centre in the years 1998-2007, were 
assessed. Out of that number, 217 were not found to be carriers of the known pathogenic  
mutations and were diagnosed as having sporadic medullary thyroid cancer. All patients with 
diagnosed sMTC were examined in respect of occurrence of other germline mutations in 
exons: 10, 11, 13, 14, 15 and 16, in which changes connected with hereditary MTC were 
detected.  The other 29 patients were found to be carriers of mutations in codons 791 (9 
patients) and 634 (19 patients). 
Assessments were also performed in 11 non-affected carriers of codon 791 mutations 
and 3 non-affected carriers of codon 634 mutations. 
All  patients  were  subjected  to  the  following  standard  diagnostic  procedures: 
laboratory tests for  serum CEA and calcitonin  (basal  and in some cases also stimulated 
levels),  calcium,  PTH,  catecholamines  and  their  urinary  metabolites,  neck  ultrasound 
scanning,  abdominal  ultrasound  scanning  including  adrenal  gland  area  evaluation, 
echocardiography  and  ABP  (ambulatory  blood  pressure  monitoring).  Peripheral  blood 
sample was taken for genetic testing.
The frequency of occurrence of molecular variants in the population was evaluated by 
testing anonymous blood samples of neonates from Central Poland. The presence of the 
L769L and S904S molecular variants were analyzed in 420 blood samples and of the S836S 
molecular variant in 411 blood samples. 
Methods
The genomic DNA of the studied individuals was isolated from peripheral blood 
lymphocytes. Four fragments of the RET gene: exons 13, 14, 15 and 11 were amplified using 
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the PCR technique, in which the frequency of occurrence of SNP was studied. The product 
of the sequencing reaction was subjected to electrophoresis on 5% denaturing 
polyacrylamide gel in a Perkin Elmer ABI Prism 377 DNA sequencer. Detailed information 
can be found in publication Paszko et al 2007 (6).
 Statistical Analysis  
The statistical analysis of the frequency of polymorphic variants was performed using 
Chi-square  (χ2)  test  with  Yates'  Correction.  The difference calculated with  the probability 
margin of p<0.05 was deemed statistically significant. When analyzing the age at onset of the 
disease in the studied groups, median ages at onset were compared using Mann-Whitney 
test.
Bioinformatics Analysis
mRNA sequence was taken from NCBI nucleic database, divided to shorter parts – 
exons - and folded by RNAfold software from RNA ViennaPackage (14). RNAfolding 
algorithm counts energy parameters, and their values depend on sequence length. The 
reason is that if RNA molecule is long enough, the probability of the predicted structure with 
minimal free energy (MFE) is very low, because the amount of possible secondary structure 
grows expotentially with the length of the sequence. In these experiments we wanted to 
observe the possible influence of one nucleotide change on the energy of the sequence. This 
change cannot be observed if we consider the whole RET sequence – its length is 3345 
nucleotides. Considering small fragments, allows us to observe local energy parameters and 
stabilization differences. The structures were visualized by VARNA software (Visualization 
Applet for RNA) (15).
RESULTS
A total of 124 cases of homo- and heterozygous molecular variants L769L (57.14%) 
were identified in the 217 MTC patients assessed; 202 cases of homo- and heterozygous 
molecular variants L769L (48.09%) were identified in the 420 samples collected from the 
control group, OR: 1.43; p=0.0374. The frequency of the individual alleles in the case of the 
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polymorphic change L769L differed from the frequency of these alleles in the control group. 
χ2  statistical  analysis  showed  these  differences  to  be  statistically  significant,  OR:  1.43; 
p=0.0394, Table 1.
The analysis of the polymorphic variant S836S in exon 14 and S904S in exon 15 of 
the RET gene showed no statistically significant difference in the frequency of heterozygotes 
and homozygotes between MTC patients and non-affected individuals. Table 1.
Furthermore, we analyzed whether the presence of the polymorphic change L769L in 
patients with sporadic medullary thyroid carcinoma affected the age at onset of the disease. 
Thus, using Mann-Whitney test we compared the median ages at onset of the disease in the 
three groups of MTC patients carrying different polymorphic variants: CTT/CTT, CTT/CTG 
and CTG/CTG, Table 2. The results showed that the age at onset of the disease in carriers 
of the homozygous polymorphic change CTG/CTG was 11.5 years lower than the age at 
onset  in  individuals  with  the  wild-type  nucleotide  sequence  CTT/CTT.  The  difference 
between the median ages at onset between these two groups was statistically significant 
(p=0.021). Similarly, the age at onset in carriers of the homozygous change CTG/CTG was 
14.5  years  lower  than  the age of  affected carriers  of  heterozygous  polymorphic  change 
CTT/CTG. The difference between the compared groups was also statistically  significant 
(p=0.015), Table 2.
In  the  studied  group  of  MTC  patients  the  polymorphic  change  L769L  was 
accompanied by a F791Y mutation in exon 13. Each patient carrying mutation F791Y had at 
the same time SNP L769L, Table 3. The most frequently occurring mutation in the studied 
patients was the RET exon 11 codon 634 mutation. In carriers of these mutations at codon 
634 (C634R,  C634S,  C634G)  the polymorphic  change L769L occurred in  only  59,0% of 
cases, Table 3. The age at onset in carriers of  RET codon 634 mutations and SNP L769L 
was 23 years lower than in patients carrying only the mutation at codon 634. The difference 
between the median ages at onset in both groups of patients was significant p=0.0072, Fig. 1
The obtained results induced us to carry out bioinformatics analysis of the changes 
that may occur during genetic information reading of the studied RET gene fragments. The 
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simplest  prediction  of  mRNA structure is  a prediction of  thermodynamic  stable  structure, 
minimal  free  energy  structure  (MFE).  The  result  of  this  method  is  shown  in  Table  4. 
Differences in minimal free energy between wild types and mutants are less than 5% in the 
case of SNP's S904S, S836S and mutations Y791F and C634R. No effect on MFE is visible 
also in the combination of C634R and SNP L769L.
Only in the case of exon 13 and SNP the difference is noticeable. SNP reduces the energy of 
the wild-type by 17%, and the mutant Y791F by 7%. It can be concluded that only SNP 
L769L reduces the minimal free energy of small mRNA fragment (in the longer part of 
sequence – from exon 11 to 13, the effect is not visible). Fig. 2 shows the predicted MFE 
structures of exon 13. The effect of one mutated nucleotide is visible – it changes the MFE 
structure in wild type and mutated sequence.
However, it is known that mRNA is unlikely to adopt a single stable conformation. It 
rather exists as a population of structures - RNA molecules fold to a metastate, which 
alternates between a number of closely related structures (16). Therefore recently ensemble-
based approaches to structure prediction are more popular. The results of ensemble diversity 
and the free energy of the thermodynamic ensemble are shown also in Table 4.  Evident 
differences between exons are visible in case of ensemble diversity (the average base-pair 
distance between all structures in the Boltzmann ensemble).The base-pair distance is 
defined as the number of base-pairs not shared by two structures. Lower ensemble diversity 
means that more base pairs are shared in the ensemble of predicted structures, so RNA 
structure is more stable.
All tested mutations reduced the value of ensemble diversity. Pathogenic mutations 
have negligible effect: Y791F reduce the value by 6.6% and C634R only by 1.86%. On the 
other hand, SNPs reduced S836S by 13% and SNP S904S by 29%. 
Greater change is visible in the fragment of joined exons (11, 12, 13): SNP L769L reduces 
the ensemble diversity of exon 13 by 10.68% and of exon having a pathogenic mutation 
(C634R) by 10.91%. Again, the greatest change is visible in exon 13: SNP L769L reduces 
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the ensemble diversity of exon 13 up to 76% and of exon having a pathogenic mutation 
(Y791F) up to 53%.
DISCUSSION
The assessment of the occurrence of the three polymorphic changes L769L, S836S 
and  S904S  in  patients  with  sporadic  medullary  thyroid  carcinoma  and  in  non-affected 
individuals, demonstrated in our study differences in the frequency of polymorphism L769L in 
exon  13  of  the  RET gene.  The  differences  in  the  frequency  of  heterozygous  changes 
(CTT/CTG) were statistically significant  as determined by the χ2  statistical  analysis.  Many 
authors  differ  in  their  opinions  as  to  the  effect  of  the  polymorphic  variants  on  the 
predisposition to develop sporadic MTC. Several authors found no significant differences in 
the frequency of polymorphic changes L769L, S836S and S904S in patients with sporadic 
and familial medullary thyroid carcinoma as compared with the control group (17, 18, 19, 20, 
21, 22, 23, ). Baumgartner-Parzer et al. (12), suggested that the discrepancy in the results of 
studies on the occurrence of polymorphic variants in exons 13 and 14 of the RET gene were 
due to ethnic  differences in  the studied population of  MTC patients or  differences in  the 
criteria  of  selection  of  the  assessed  MTC patients  and  in  particular  in  the  selection  of 
individuals for the control group.
The frequency of the polymorphic change L769L in exon 13 in the MTC affected and 
non-affected population of  Central  Poland was found to be higher  then the frequency of 
these changes in other countries, Table 1. The highest frequency of the polymorphic change 
L769L has so far been observed in Turkey and it was 29% of the MTC-affected population. 
The least frequent occurrence of SNP L769L was reported in the population of Brazil where it 
accounted for 13% of MTC patients and in Portugal (16% and 18% in MTC patient population 
and non-affected individuals, respectively) (20). Studies performed by Wiench  et al. in the 
Polish population of Silesia Province in 2004 showed the frequency of polymorphism L769L 
in MTC patients and the control group to be 23% and 27%, respectively. The dissimilarity of 
results obtained by  Wiench et  al. (22)  and in  our  study was  most  likely  due to regional 
differences in the frequency of the polymorphic variants in the Polish population.
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An important aspect of our study was to investigate the effect of the presence of the 
polymorphic change L769L in the  RET gene on the age at onset in patients with sporadic 
MTC. We found that the age at onset in carriers of the homozygous change L769L was 
significantly  lower  than in  carriers of  the wild  nucleotide,  Table 2.  These findings  clearly 
showed that homozygous polymorphic changes could act as modifiers in the development of 
sporadic medullary thyroid carcinoma.  Wiench et al. (22) found increased frequency of the 
L769L  polymorphism  in  younger  (aged  <30)  patients  with  sporadic  MTC  from  Silesia 
Province,  however,  the difference in frequency compared with the control  group was not 
statistically significant. Gursoy et al. (20) however, found no significant differences in the age 
at  onset  of  sporadic  MTC  between  younger  patients  (under  40  years  of  age)  carrying 
polymorphism L769L and the group of older patients (over 40 years of age).
We have made an interesting observation concerning carriers of pathogenic germline 
mutations at codon 634 and the polymorphic variant L769L. Apparently, the age at onset of 
the disease in carriers of the germline mutation and the polymorphic variant was lower than 
in carriers of only the RET codon 634 pathogen mutation, Fig. 1.
In our material, similarly as Baumgartner-Parzer et al. (12), we found that individuals 
harbouring a RET codon 791 mutation always harboured the L769L polymorphism as well. 
As the most recent data (6, 24) suggested, mutation F791Y may be much  more frequent 
than it had previously been thought to occur.
In  the studied material,  unlike  in  the case of  the polymorphic  change L769L,  the 
analysis of the frequency of the polymorphic variant S836S occurring in exon 14 of the RET 
gene  showed  no  statistically  significant  differences  in  the  frequency  of  heterozygous 
polymorphisms  between  patients  with  sporadic  MTC and  the  control  group.  Our  results 
match the findings of  other authors (12,  13; 22, 25) who found no significant differences in 
the  frequency  of  these  changes  between  patients  with  sporadic  MTC  and  non-affected 
individuals.
However, many authors (26, 27, 28) claim that the molecular variant S836S in the 
RET gene  plays  a  more important  role  in  the  pathogenesis  of  MTC.  Griseri  et  al. (29), 
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suggested  that  the  polymorphic  variant  S836S  could  increase  RET receptor  TK activity 
(similarly to the germline gain-of-function mutation). In the authors’ opinion, the polymorphic 
change S836S could lead to incorrect  protein synthesis  or amino acid substitution in the 
protein caused by similarity and erroneous recognition of aminoacyl-tRNA. 
Robledo et al. (30) noticed that G691S/S904S haplotype of  RET may influence the 
age at onset in MEN2A patients. The change G691S is mainly responsible for that effect, 
however it cannot be ruled out that polymorphic change S904S can lead to production of 
different amounts of mRNA. The frequency of the polymorphic change S904S in our study 
population is similar  in the study and control  groups.  The occurrence of the polymorphic 
change itself  is,  probably,  not  a factor  predisposing to MTC development.  It  is  possible, 
however, that the occurrence of that polymorphic variant, accompanying other more serious 
changes, can accelerate and modify the oncogenic effect induced by those changes. 
The mechanisms by which polymorphic changes in the RET gene affect synthesis of 
the protein encoded by this gene are still not properly understood. It is presumed that their 
activity results in interrupted transcript splicing. As early as in the late 90s, Borrego et al. (26) 
put  forward  a thesis  that  polymorphic  variants  may cause new,  alternative  splicing  sites 
(acceptor, donor or enhancer) to appear, which lead to the synthesis of incomplete proteins 
or erroneous ligand binding, microRNA binding, change of structure and mRNA stability as 
well  as a number of  copies and also  the change in the structure of  proteins caused by 
interference  (slowing  down)  of  translation  (31,  32) Our  analyses  based  on  bioinformatic 
methods made possible to draw several conclusions concerning mRNA conservation in the 
case of presence of various polymorphic variants in the RET gene.
Codon usage bias refers to differences among organisms in the frequency of 
occurrence of synonymous codons in mRNA. Optimal codons reflect the composition of their 
respective genomic tRNA pool. It is thought that using optimal codons help to achieve faster 
translation rates and higher accuracy. Folding of the beta sheet occurs slower than the alpha 
helix formation (33). If translation rate is changing before the process of beta sheet formation 
is finished, newly synthesized sequence influence the structure earlier (or later) then usual 
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and may effect on the folding of the protein. If the mutation is a change of optimal to less 
frequent codon, it can lead to translation or protein folding disorders, because of ribosome 
stalling (pause). SNP S836S and S904S are changes to less frequent codons, so ribosome 
stalling can happen. In case of SNP L679L, where the codon with higher codon usage 
appear, the sheet may not finish creating the structure, when helix appears (34), Tab.5. As a 
consequence, there is not enough space to create the appropriate structure. This can lead to 
changes in kinase activity and/or specificity and, as a result, influence disease sympthomes. 
We may thus assume, on the basis of the studies conducted, that the molecular polymorphic 
variants in the RET gene play a very important role in the predisposition to sporadic 
medullary thyroid carcinoma and modify the age at onset of this disease.
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Legend
Fig.1 Relationship between presence of SNP L769L and the age at onset of MTC symptoms in 
pathogenic 634 mutation carriers.
Fig.2 Minimal free energy (MFE) structures of mutated exon 13: A – wild type, B – pathogenic 
mutation, C – synonymous mutation ( SNP L769L, CUU → CUG), D – pathogenic mutation and 
synonymous mutation. 
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Fig. 2
Tab.1 Allele frequencies of three exonic RET SNPs: L769L, S836S and S904S in sporadic MTC patients and controls. 
(A) number of hetero- or homozygous subjects, (T) total number of sMTC patients, (N) total number of control individuals
Allele
 sporadic MTC (%) control (%)
OR (95%CI) Statistic significance
A / T (%) A / N (%)
SNP L769L
CTT/CTG 105/217 (48.3) 166/420 (39.5) 1.43 (1.03-1.99) p=0.0394*
CTG/CTG 19/217 (8.7) 36/420 (8.5) p=0.9374
CTT/CTG + CTG/CTG 124/217 (57.14) 202/420 (48.09) 1.43 (1.03-2.00) p=0.0374*
SNP S836S
AGC/AGT 14/217 (6.4) 28/411 (6.8) p=0.8633
AGT/AGT 0/217 (0.0) 2/411 (0.4) p=0.7760
AGC/AGT + AGT/AGT 14/217 (6.45) 30/411 (7.3)  p=0.6923
SNP S904S
TCC/TCG 66/217 (30.4) 135/420 (32.14) p=0.7227
TCG/TCG 8/217 (3.6) 8/420 (1.9) p=0.2735
TCC/TCG + TCG/TCG 74/217 (34.1) 143/420 (34.0) p=0.9892
Tab 2. Age at onset of symptoms for sMTC (median) in patients with different sequence variants in codon 769 RET gene in whom no RET 
pathogenic mutation was found. 
Median of age (years) at onset of sMTC symptoms Statistical significance
CTT/CTT n=89 CTT/CTG n=103 CTG/CTG n=18 Alleles compared
A B C A/B A/C B/C
52 (15-85) 55 (18-83) 40.5 (22-70) p=0.63 p=0.021* p=0.015
The research covered a group of 210 patients for whom age at onset of symptoms of sporadic MTC could be established
Wild type(A), heterozygous change (B), homozygous change (C). All patients were non-carriers of pathogenic mutations in gene RET.
Tab.3 The frequencies of RET variants 769/CTG, 836/ATG and 904/CTG in carriers of pathogenic mutations 791 and 634.
Number of hetero-and homozygous carriers of SNP / Total number of mutation carriers (%)
  Mutation: F791Y Mutations: C634R, C634S, C634G
SNP: L769L 20 / 20 (100) 13 / 22 (59,0)
SNP: S836S 0 / 20 (0) 2 / 23 (8.6)
SNP S904S 3/14 (21,4) 7/15 (46,6)
Tab. 4 Energy parameters of predicted RNA structures for selcted exons without (WT – wild type) and with mutations: exon 13 with pathogenic mutation Y791F (TAT→TTT) 
and/or synonymous mutation SNP L769L (CUU → CUG); exon 14 with synonymous mutation SNP S836S (AGC → AGU); exon 15  with synonymous mutation SNP S904S 
(UCC → UCG); exons 11-13 with pathogenic mutation C634R (TGC → CGC) and/or synonymous mutation SNP L769L (CUU → CUG).
Minimum free energy, ensemble diversity and the free energy of the thermodynamic ensemble are predicted by RNAfold software as described in materials and methods.
WT
(Fig. 1A)
Mut 791
(Fig. 1C)
Mut 791 + 
L769L
(Fig. 1B)
L769L
(Fig. 1D) WT S836S WT S904S WT Mut C634R L769L
Mut C634R
+ L769L
Minimum free 
energy  (MFE)
[kcal/mol]
-31,9 -32,7 -35 -37,4 -94,1 -93 -42,7 -42,4 -196,9 -198,9 -203,5 -205,5
The ensemble 
diversity 38,98 36,41 17 9,11 63,82 55,61 23,08 18,38 96,38 94,59 86,09 84,27
The free energy
of the 
thermodynamic 
ensemble
[kcal/mol]
-35,53 -35,49 -37,91 -39,63 -97,63 -97,41 -45,94 -45,42 -213,92 -220,39 -215,57 -186,4
Exon 13       Exon 14 Exon 15 Exon 11-13
Tab. 5 Codon Usage comparison. Values of codon usage (frequency per thousand) in Homo sapiens were 
taken from Codon Usage Database [36].
SNP Codon change Codon Usage (Hom Sapiens)
L769L CUU → CUG 13,2 → 39,6
S836S AGC → AGU 19,5 → 12,1
S904S UCC → UCG 17,7 → 4,4
1
